U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer and wants the U.S. drug giant to make ...

The smart money seems to be calling a bottom for the healthcare sector. That could mean it’s time for investors to start taking another look at the industry’s more beleaguered stocks. Since the start ...

This recovery should alleviate concerns about dividend sustainability and provide the financial flexibility needed for strategic investments. From a valuation perspective, Pfizer's stock is highly ...

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

A recent report released by Oliver Wyman ... Rather than expecting specialist sustainability teams within companies to drive change across the whole business, the consulting firm recommends ...

In today’s fast-paced world, finding the right marketing agency can feel overwhelming. With so many options, it’s ...

Under the guise of combating “woke” investing, corporate-backed House Republicans last week passed legislation that would ...

Pfizer CEO Albert Bourla reportedly is planning to meet with Starboard Value after the activist investor took a $1 billion ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Pfizer shares have gained ground since a report over the weekend said that activist investor Starboard Value has taken a roughly $1 billion stake in the drug maker and is pushing for changes. Monitor ...

Citing people familiar with the matter, The Journal reported that Starboard approached former Pfizer CEO Ian Read and CFO ...